

Exhibit 15

7/17/15 Letter from NIH Deputy Director to Congressional Representatives



JUL 17 2015

The Honorable Alcee L. Hastings
House of Representatives
Washington, D.C. 20515

Dear Representative Hastings:

Secretary Burwell has asked the National Institutes of Health (NIH) to respond to your recent letter regarding alleged animal mistreatment at Primate Products, Inc. (PPI).

HHS acquisition regulations require all vendors providing non-human primates to our programs, including PPI, to possess a Public Health Service (PHS) Animal Welfare Assurance with the NIH Office of Laboratory Animal Welfare (OLAW) and to maintain compliance with the PHS Policy on Humane Care and Use of Laboratory Animals (Policy). OLAW is investigating this matter and we are awaiting the outcome of its investigation.

Under the Memorandum of Understanding between the NIH and the U.S. Department of Agriculture (USDA), OLAW was notified by USDA on May 27, 2015, about allegations of noncompliance with the PHS Policy at PPI. On June 1, 2015, OLAW received from the People for the Ethical Treatment of Animals an additional extensive list of allegations of noncompliance which an undercover informant had gathered. The submission included written and video documentation of improper handling and treatment of nonhuman primates at the institution. OLAW sent a letter to PPI on June 5 and directed PPI to address all of the allegations and to provide a specific plan and schedule for corrections for identified noncompliance. PPI has been given the opportunity to take corrective action, and, if no action is taken, their Assurance will be revoked leading to revocation of associated contracts. On July 1, PPI submitted their initial responses to OLAW (as well as to the USDA). OLAW will review the responses and continue to investigate to determine whether PPI is in compliance. This will take time as there were substantive issues to address. During the time that this matter is under investigation by OLAW, all contract activities with PPI are suspended.

Thank you for your commitment to public health. A copy of this letter was also sent to Representative Lois Frankel and Representative Theodore Deutch.

Sincerely,

A handwritten signature in black ink, appearing to read "Lawrence Tabak", written over a horizontal line.

Lawrence Tabak, D.D.S., Ph.D.
Deputy Director



JUL 17 2015

The Honorable Theodore Deutch
House of Representatives
Washington, D.C. 20515

Dear Representative Deutch:

Secretary Burwell has asked the National Institutes of Health (NIH) to respond to your recent letter regarding alleged animal mistreatment at Primate Products, Inc. (PPI).

HHS acquisition regulations require all vendors providing non-human primates to our programs, including PPI, to possess a Public Health Service (PHS) Animal Welfare Assurance with the NIH Office of Laboratory Animal Welfare (OLAW) and to maintain compliance with the PHS Policy on Humane Care and Use of Laboratory Animals (Policy). OLAW is investigating this matter and we are awaiting the outcome of its investigation.

Under the Memorandum of Understanding between the NIH and the U.S. Department of Agriculture (USDA), OLAW was notified by USDA on May 27, 2015, about allegations of noncompliance with the PHS Policy at PPI. On June 1, 2015, OLAW received from the People for the Ethical Treatment of Animals an additional extensive list of allegations of noncompliance which an undercover informant had gathered. The submission included written and video documentation of improper handling and treatment of nonhuman primates at the institution. OLAW sent a letter to PPI on June 5 and directed PPI to address all of the allegations and to provide a specific plan and schedule for corrections for identified noncompliance. PPI has been given the opportunity to take corrective action, and, if no action is taken, their Assurance will be revoked leading to revocation of associated contracts. On July 1, PPI submitted their initial responses to OLAW (as well as to the USDA). OLAW will review the responses and continue to investigate to determine whether PPI is in compliance. This will take time as there were substantive issues to address. During the time that this matter is under investigation by OLAW, all contract activities with PPI are suspended.

Thank you for your commitment to public health. A copy of this letter was also sent to Representative Alcee Hastings and Representative Lois Frankel.

Sincerely,

A handwritten signature in black ink, appearing to read "Lawrence Tabak", with a stylized flourish at the end.

Lawrence Tabak, D.D.S., Ph.D.
Deputy Director



JUL 17 2015

The Honorable Lois Frankel
House of Representatives
Washington, D.C. 20515

Dear Representative Frankel:

Secretary Burwell has asked the National Institutes of Health (NIH) to respond to your recent letter regarding alleged animal mistreatment at Primate Products, Inc. (PPI).

HHS acquisition regulations require all vendors providing non-human primates to our programs, including PPI, to possess a Public Health Service (PHS) Animal Welfare Assurance with the NIH Office of Laboratory Animal Welfare (OLAW) and to maintain compliance with the PHS Policy on Humane Care and Use of Laboratory Animals (Policy). OLAW is investigating this matter and we are awaiting the outcome of its investigation.

Under the Memorandum of Understanding between the NIH and the U.S. Department of Agriculture (USDA), OLAW was notified by USDA on May 27, 2015, about allegations of noncompliance with the PHS Policy at PPI. On June 1, 2015, OLAW received from the People for the Ethical Treatment of Animals an additional extensive list of allegations of noncompliance which an undercover informant had gathered. The submission included written and video documentation of improper handling and treatment of nonhuman primates at the institution. OLAW sent a letter to PPI on June 5 and directed PPI to address all of the allegations and to provide a specific plan and schedule for corrections for identified noncompliance. PPI has been given the opportunity to take corrective action, and, if no action is taken, their Assurance will be revoked leading to revocation of associated contracts. On July 1, PPI submitted their initial responses to OLAW (as well as to the USDA). OLAW will review the responses and continue to investigate to determine whether PPI is in compliance. This will take time as there were substantive issues to address. During the time that this matter is under investigation by OLAW, all contract activities with PPI are suspended.

Thank you for your commitment to public health. A copy of this letter was also sent to Representative Alcee Hastings and Representative Theodore Deutch.

Sincerely,

A handwritten signature in black ink, appearing to read "Lawrence Tabak".

Lawrence Tabak, D.D.S., Ph.D.
Deputy Director